Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam in Mild-to-Moderate Alzheimer's Disease
NCT03748706Phase 2Completed
- Sponsor
- Cassava Sciences
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of simufilam in Alzheimer's disease (AD), sponsored by Cassava Sciences. Started Mar 2019; status: completed.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03748706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748706.